Ageing, Cognitive Impairment, Digital Health, Frailty, Multidisciplinary Approach, Quality of Life, Sleep Disorders
Conditions
Brief summary
The goal of this observational study is to learn about the effects of sleep disorders on health and ageing in older people over the age of 65. The main question it aims to answer is: How do sleep disorders impact the motoric and cognitive ageing trajectories of older individuals? Participants will undergo a set of instrumental, laboratory and clinical diagnostic examinations to comprehensively assess the impact of sleep disorders on health.
Interventions
None listed
Sponsors
University of Parma
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age ≥ 65 years; * MMSE score adjusted by age and education ≥ 25/30; * Absence of mobility-disability; * Absence of need for assistance with Basic Activities of Daily Living (according to the ICFSR International Clinical Practice Guidelines).
Exclusion criteria
* Individuals with specific clinical conditions that make the intervention unsafe (I.e., severe diseases, unstable health status); * Individuals whose adherence to the protocol might be low due to clinical (E.g., cognitive impairment, dialysis) and non-clinical (E.g., plans to relocate out of the study area within the next 3 years) reasons; * Individuals unable or unwilling to provide informed consent; * Consumption of more than 14 alcoholic drinks per week \[one alcoholic drink (equal to 14.0 grams of pure alcohol) corresponds to 36 cc of beer (5% alcohol content), 24 cc of malt liquor (7% alcohol content), 15 cc of wine (12% alcohol content), 4.5 cc of distilled spirit or liquor (40% alcohol content)\]; * Difficulty in communicating with the study staff due to speech, language, or (non-corrected) hearing and vision problems; * Severe arthritis (E.g., awaiting joint replacement) that would interfere with the ability to fully participate in the study; * Lung disease requiring regular use of supplemental oxygen; * Severe cardiovascular disease (including New York Heart Association \[NYHA\] class III or IV, clinically significant congestive heart failure and valvular disease, history of cardiac arrest, presence of an implantable defibrillator or pacemaker, uncontrolled angina); * Upper and/or lower extremity amputation; * Peripheral arterial disease Lériche-Fontaine 3 or 4; * Renal disease requiring dialysis; * Current enrolment in another study involving lifestyle, nutrition, or pharmaceutical interventions; * Further medical, psychiatric, or behavioural factors that in the judgment of the principal investigator may interfere with the study participation; * Further possible illnesses affecting the life expectancy and reducing it to less than 24 months, corresponding to the study's length; * Clinical judgment concerning safety or non-compliance, as well as the conditions for which the use of the Sleep Profiler is not recommended (sensitivity of skin or scalp and/or open wounds on the forehead or scalp, allergic reactions to extended exposure to synthetic fabrics (e.g., polyester, rayon), upper respiratory infection or congestion, head circumference less than 21 or greater than 25 inches, forehead vertical measurement (from top of eyebrows to hairline) less than or equal to 2 inches or horizontal measurement (from hairline to hairline) less than or equal to 6 inches). * SPPB score \<3 at baseline.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of physical and functional worsening | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Prevalence of mild cognitive impairment (MCI) and cognitive frailty | 24 months |
| Incidence of mild cognitive impairment (MCI) and cognitive frailty | 24 months |
| Prevalence and incidence of sarcopenia | 24 months |
| Prevalence and incidence of recognised pre-frailty conditions | 24 months |
| Prevalence and incidence of malnutrition, polypharmacy and multimorbidity | 24 months |
| Incidence of dementia in cognitive frail older individuals | 24 months |
Contacts
Primary ContactMarcello G Maggio
Outcome results
None listed